Chemical subgroup
L01XK – Poly-ADP-Ribose-Polymerase (PARP)-Inhibitoren
17Decisions
24Patient groups
Added benefit by patient group
- Considerable6
- Minor3
- Not proven14
- Lesser benefit1
Decisions, newest first
- 2026-09-03AkeegaNiraparib/AbirateronacetatNot proven: 2 of 2 patient groups
- 2025-02-20LynparzaOlaparibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-08-15TalzennaTalazoparibNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2024-06-06RubracaRucaparibNot proven
- 2024-05-02AkeegaNiraparib/AbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-09-21RubracaRucaparibNot proven
- 2023-09-21LynparzaOlaparibNot proven
- 2023-07-06LynparzaOlaparibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-04-20LynparzaOlaparibConsiderable
- 2023-02-16LynparzaOlaparibMinor
- 2021-07-15ZejulaNiraparibNot proven
- 2021-06-03LynparzaOlaparibConsiderable
- 2021-06-03LynparzaOlaparibNot proven
- 2021-05-20ZejulaNiraparibNot proven
- 2020-11-20TalzennaTalazoparibConsiderable
- 2020-01-16LynparzaOlaparibMinor
- 2018-12-06LynparzaOlaparibMinor
Data status: 2026-10-29